Nelson M A, Wymer J, Clements N
Arizona Cancer Center, College of Medicine, University of Arizona, Tucson 85724 USA.
Cancer Lett. 1996 May 15;103(1):115-21. doi: 10.1016/0304-3835(96)04202-4.
Oncogene and tumor suppressor gene mutations are candidate biomarkers for cancer risk assessment and lesion detection. The K-ras oncogene has previously been associated with non-small cell lung cancer (NSCLC), particularly adenocarcinomas in which reported rates of mutation have approached 30-40%. We have analyzed non-malignant lung tissue from patients with lung cancer and primary lung cancers for K-ras gene mutations. Mutations were detected in 32% cancers and 29% non-malignant lung tissue from patients with cancer. The majority of tumors testing positive were adenocarcinoma of the lung. Normal DNA controls, including peripheral blood lymphocytes and normal lung from non-smokers, were negative. The ability to detect genetic alterations in non-malignant lung tissues is consistent with the concept that genetic alterations are involved in field cancerization of the aerodigestive tract.
癌基因和肿瘤抑制基因突变是癌症风险评估和病灶检测的候选生物标志物。K-ras癌基因此前已被证实与非小细胞肺癌（NSCLC）相关，尤其是腺癌，其报道的突变率接近30%-40%。我们分析了肺癌患者的非恶性肺组织和原发性肺癌中的K-ras基因突变情况。在32%的癌症和29%的癌症患者非恶性肺组织中检测到了突变。检测呈阳性的大多数肿瘤为肺腺癌。包括外周血淋巴细胞和非吸烟者的正常肺组织在内的正常DNA对照均为阴性。在非恶性肺组织中检测到基因改变的能力与基因改变参与气消化道场癌变的概念相一致。
